Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How to reduce plasma-induced damage during reactive ion etching of low-k dielectrics in sub-7 nm logic nodes — chemistry, pulsed RF, ALE, and passivation strategies.
Article | Report RNA silencing, TTR stabilizers, CRISPR editing, and monoclonal antibodies are reshaping the ATTR amyloidosis pipeline beyond patisiran. Explore the IP landscape.
Article | Report VRFB electrolyte technology landscape 2026: concentration enhancement, additive science, hybrid redox couples, and non-aqueous systems mapped across 40 years of patents.
Article | Report How interface trap density at gate dielectric boundaries drives threshold voltage instability in GaN power HEMTs — mechanisms, measurement, and mitigation strategies.
Article | Report How interface trap density at gate dielectric boundaries drives threshold voltage instability in GaN power HEMTs — mechanisms, measurements, and mitigation strategies.
Article | Report Gene therapy, cardiac regeneration, and structural defect correction approaches in the CHD drug pipeline — AAV vectors, RNA therapeutics, organoids, and more.
Article | Report Patent landscape analysis of transparent conductive electrode (TCE) technology in 2026: metal mesh, ITO alternatives, carbon-based, and stretchable architectures mapped across 5 material families.
Article | Report mTOR inhibitors, AAV gene therapy, ganaxolone, and ASO strategies shaping the TSC drug pipeline. A patent-intelligence analysis by PatSnap Insights.
Article | Report How SOD1 ASOs, TDP-43 splice-switch oligonucleotides, anti-TDP-43 antibodies, and neurofilament biomarkers are reshaping the ALS drug pipeline. Patent intelligence analysis.
Article | Report How does microfluidic chip-based cell sorting compare to FACS for CAR-T therapy? Patent data reveals a 100x sensitivity gain and closed-system sterility advantages.
Article | Report Analyse the progressive MS drug pipeline: BTK inhibitors, remyelination strategies, and neuroprotection approaches. Patent intelligence from PatSnap Eureka.
Article | Report How XAI mechanisms help clinical decision support systems meet EU AI Act transparency, auditability, and compliance requirements. Patent analysis from 8 key filings.
Article | Report VMAT2 inhibitors dominate the tardive dyskinesia drug pipeline. Explore patent landscape analysis of valbenazine, deutetrabenazine, PDE7/PDE10 inhibitors, and emerging gene therapy approaches.
Article | Report How closed-loop quality control, fracture-mechanics thresholds, and inter-process correlation enable zero-defect manufacturing in high-volume automotive stamping.
Article | Report Explore next-generation smoking cessation drugs: nicotinic receptor partial agonists, 5-HT2C agonists, anti-nicotine antibodies, cannabinoids, and botanical approaches in the patent pipeline.